CLYM.US Climb Bio Inc

Healthcare Biotechnology USA Stocks
10.36 USD
Close of Nov 14, 2026
1.64 18.33
Market cap
USD 609M
P/E
-
P/B
2.80x
ROE
-24.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CLYM.US undervalued?

Graham number

The Graham number of Climb Bio Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Climb Bio Inc fundamental analysis

No fundamental analysis for Climb Bio Inc yet.

Climb Bio Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Climb Bio Inc

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial in…

Full company profile